However, the ability of FCBD to reduce ACE2 expression should be examined at both the protein and functional levels (e.g., binding of the viral protein) to fully determine the effect FCBD may have on ACE2-related treatment of COVID-19 patients. This evidence concerns the gene ACE2 and COVID-19.